Skip to main content
Log in

Orale Tolvaptan-Therapie

Ist diese sicher und effektiv zur Behandlung der chronischen Hyponatriämie?

Oral Tolvaptan

Its safety and effectivity in chronic hyponatremia

  • Für Sie gelesen
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099–2112

    Article  CAS  PubMed  Google Scholar 

  2. Berl T, Quittnat-Pelletier F, Verbalis JG et al (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21:705–712

    Article  CAS  PubMed  Google Scholar 

  3. Renneboog B, Musch W, Vandemergel X et al (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119:71–78

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenskonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Linkermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linkermann, A., Kunzendorf, U. Orale Tolvaptan-Therapie. Nephrologe 5, 239–241 (2010). https://doi.org/10.1007/s11560-010-0437-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-010-0437-y

Navigation